We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.82%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$80.2M
AUM Growth
+$15M
(+23%)
Cap. Flow
+$9.28M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
98.34%
Holding
15
New
5
Increased
2
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$9.92M |
| 2 |
Pfizer
PFE
|
+$6.81M |
| 3 |
Biogen
BIIB
|
+$6.61M |
| 4 |
Labcorp
LH
|
+$6.53M |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$6.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$11.4M |
| 2 |
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
|
+$5.47M |
| 3 |
GNC
GNC Holdings, Inc.
GNC
|
+$3.11M |
| 4 |
Anika Therapeutics
ANIK
|
+$2.61M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Elevance Health
ELV
$83.7B
| $10.4M | 12.95% |
+55,200
| New | +$9.92M |
|
2
McKesson
MCK
$104B
| $10.4M | 12.95% |
63,100
+12,100
| +24% | +$1.83M |
|
3
Cencora
COR
$62.2B
| $10.4M | 12.93% |
109,700
-16,300
| -13% | -$1.45M |
|
4
Charles River Laboratories
CRL
$11.6B
| $7.1M | 8.86% |
70,212
-15,400
| -18% | -$1.42M |
|
|
5
Labcorp
LH
$25.8B
| $7.06M | 8.8% |
+53,311
| New | +$6.53M |
|
6
Gilead Sciences
GILD
$167B
| $6.91M | 8.61% |
97,600
-19,400
| -17% | -$1.29M |
|
|
7
Pfizer
PFE
$144B
| $6.88M | 8.58% |
+215,859
| New | +$6.81M |
|
|
8
Ligand Pharmaceuticals
LGND
$5.94B
| $6.82M | 8.51% |
+90,089
| New | +$6.3M |
|
|
9
Biogen
BIIB
$30.4B
| $6.78M | 8.46% |
+25,000
| New | +$6.61M |
|
|
10
Anika Therapeutics
ANIK
$202M
| $6.17M | 7.69% |
125,000
-56,573
| -31% | -$2.61M |
|
11
ImmuCell
ICCC
$102M
| $1.33M | 1.66% |
182,133
+13,810
| +8% | +$82K |
|
|
GNC
12
DELISTED
GNC Holdings, Inc.
GNC
| – | – |
-422,955
| Closed | -$3.11M |
|
|
ACHN
13
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-497,807
| Closed | -$2.1M |
|
|
AET
14
DELISTED
Aetna Inc
AET
| – | – |
-89,000
| Closed | -$11.4M |
|
|
OSIR
15
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| – | – |
-1,140,222
| Closed | -$5.47M |
|
Similar funds
KP
AWA
TCM
SAAM
SC
PAA
PC
BOCH
HealthInvest Partners's Q2 2017 Portfolio in Review
As of Q2 2017, HealthInvest Partners held 15 positions worth $80.2M, up 23% from $65.2M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
HealthInvest Partners deployed $9.28M of net new capital in Q2 2017, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Elevance Health: 55,200 shares worth $10.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Anika Therapeutics, an estimated $2.61M trimmed.
- HealthInvest Partners's largest Q2 2017 buy was Elevance Health: 55,200 shares worth $10.4M.
- HealthInvest Partners added most to McKesson in Q2 2017, an estimated $1.83M increase.
- HealthInvest Partners's biggest Q2 2017 reduction was Anika Therapeutics, cutting an estimated $2.61M.
- HealthInvest Partners fully exited Aetna Inc in Q2 2017, selling an estimated $11.4M.
- HealthInvest Partners's ten largest holdings make up 98% of its $80.2M portfolio in Q2 2017.
- HealthInvest Partners opened 5 new positions and closed 4 in Q2 2017.
- HealthInvest Partners's portfolio value rose 23% quarter-over-quarter to $80.2M.
Based on HealthInvest Partners's 13F filing for Q2 2017, filed 7 Aug 2017.